Intellia Therapeutics, Inc.
Financials
Valuation Metrics
Intellia Therapeutics, Inc.'s Market Cap is $1.63B. At end of 2025 it was $974M. Ranked #2048 of 3,116 in US market (top 66%), #783 of 1,472 on NASDAQ (top 53%), #145 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.63B | US#2,048/3,116 Sec#145/265 |
| Revenue | $60M | US#2,730/3,116 Sec#140/265 |
| Net Income | $-400M | US—/3,116 Sec—/265 |
| Total Assets | $857M | US#2,530/3,116 Sec#113/265 |
| Net Assets | $728M | US#1,969/3,116 Sec#83/265 |
| Employees | 377 | US#2,342/3,116 Sec#96/265 |
| Value | ||
| P/B | 2.24x | US#1,562/3,116 Sec#79/265 |
| P/S | 27.38x | US#2,881/3,116 Sec#155/265 |
| FCF Yield | -28.61% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -54.96% | US#2,692/3,116 Sec#165/265 |
| ROA | -46.66% | US#2,972/3,116 Sec#206/265 |
| Op. Margin | -711.66% | US#2,791/3,116 Sec#159/265 |
| Revenue Growth | 12.58% | US#1,052/3,116 Sec#87/265 |
| Financial Health | ||
| Debt Ratio | 17.79% | US#196/3,116 Sec#72/265 |
| Total Debt | $73M | US#2,510/3,116 Sec#137/265 |
| FCF | $-466M | US#2,892/3,116 Sec#249/265 |
| Cash | $106M | US#2,198/3,116 Sec#171/265 |
| Current Ratio | 6.65x | US#363/3,116 Sec#115/265 |
| Performance | ||
| 1Y Return | -7.61% | US#1,811/3,116 Sec#154/265 |
| 1M Return | -4.89% | US#735/3,116 Sec#52/265 |
| From 52W High | -36.90% | US#1,936/3,116 Sec#125/265 |
| 1Y MDD | -40.75% | US#1,964/3,116 Sec#125/265 |
| Trading | ||
| Volume | 3,106,319 shares | US#405/3,116 Sec#34/265 |
| Trading Value | $37M | US#1,164/3,116 Sec#77/265 |
| Per Share | ||
| EPS | $-2.86 | US—/3,116 Sec—/265 |
| BPS | $5.21 | US#2,259/3,116 Sec#125/265 |
Company Info
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.